Pipeline
Our clinical and preclinical pipeline includes wholly owned and partnered therapeutic candidates targeting difficult-to-treat cancers and other serious diseases.
Product Candidate
Preclinical
Phase 1
Phase 2
Pivotal
Partner
Zanidatamab
Zanidatamab
HER2 x HER2 Bispecific Antibody
Zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.
Zanidatamab simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. Visit Zymeworks’ Science website to learn more about zanidatamab’s unique design.
Zanidatamab has been granted Breakthrough Therapy designation for biliary tract cancer from the FDA and the CDE in China, as well as two Fast Track designations, one for previously treated or recurrent HER2-positive biliary tract cancers (BTC) and another for first-line gastroesophageal adenocarcinoma (GEA) in combination with standard of care chemotherapy. Zanidatamab also received Orphan Drug designation for the treatment of biliary tract and gastric cancers in the United States and for gastric cancer in the European Union.
Zymeworks has entered into separate agreements with each of BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab throughout various countries around world.
Product Status
Indications
- Biliary Tract Cancers
- Breast Cancer
- Gastroesophageal Adenocarcinomas
- Colorectal Cancer
- HER2-Expressing Cancers
Partner


Technology
Product Candidate
1st-Line Gastroesophageal Adenocarcinomas
Phase: Pivotal
Partner:


Product Candidate
2nd-Line Biliary Tract Cancers
Phase: Pivotal
Partner:


Product Candidate
1st-Line Gastrointestinal Cancers
Phase: Pivotal
Partner:


Product Candidate
Late-Line Breast Cancer
Phase: Phase 2
Partner:

Product Candidate
HER2-Expressing Cancers
Phase: Pre-clinical
Partner:

Zanidatamab Zovodotin
Zanidatamab Zovodotin
HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)
Zanidatamab zovodotin (ZW49) is a HER2-targeted bispecific antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin platforms technologies. Zanidatamab zovodotin combines the unique design of zanidatamab with the addition of a proprietary cytotoxin. Zanidatamab zovodotin delivers a novel auristatin (cell-killing compound) to tumor cells via a cleavable linker by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.
Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents.
Product Status
Indications
- HER2-Expressing Cancers
Technology
Preclinical
Product Candidate
ZW191
Phase: Preclinical
ZW191
Folate Receptor-⍺ Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate
ZW191 is an antibody-drug conjugate that is engineered to target a protein called folate receptor-⍺ (FR⍺) that is found on a variety of tumours. ZW191 delivers a toxic chemotherapy, topoisomerase-1 inhibitor, to these tumour cells to kill the cancer.
ZW191 is currently in the IND-enabling stage of development.
Product Status
Indications
- Ovarian Cancer & Gynaecological Cancers
Technology
Product Candidate
ZW171
Phase: Preclinical
ZW171
2+1 MSLN x CD3 Bispecific Antibody
ZW171 is a bispecific antibody that is designed to co-engage tumor cells and immune cells (T cells) to enable T cell-mediated killing of tumor cells. ZW171 binds the tumor target mesothelin (MSLN) which is expressed on many different tumors including pancreatic and ovarian cancer. Our team engineered and optimized the antibody design using the Azymetric™ and EFECT™ technologies.
ZW171 is currently in preclinical development, projected to enter Phase I clinical trials in 2024.
Product Candidate
ZW251
Phase: Preclinical
ZW251
Glypican-3 Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate
ZW251 is the first antibody-drug conjugate engineered to target a protein called glypican-3 (GPC3), which is found on a difficult to treat liver cancer, hepatocellular carcinoma (HCC). The antibody is uniquely designed to bind strongly to the GPC3 protein, then deliver its toxic chemotherapy, topoisomerase-1 inhibitor, to kill the cancer cells.
ZW251 is currently in the IND-enabling stage of development.
Product Candidate
ZW220
Phase: Preclinical
ZW220
NaPi2b Targeted Topoisomerase 1 Inhibitor Antibody Drug Conjugate
ZW220 is an antibody drug conjugate engineered to target a protein called sodium-dependent phosphate transporter 2b (NaPi2b). The antibody is designed to bind to the NaPi2b protein that is found on some ovarian and lung tumours, and deliver its toxic chemotherapy, a topoisomerase1 inhibitor, to kill the cancer.
ZW220 is currently in the IND-enabling stage of development.
Partners
Product Candidate
Bispecific
Phase: Pre-clinical
Partner:

Product Candidate
XB002 Tissue Factor ADC
Phase: Phase 1
Partner:

XB002 Tissue Factor ADC
Product Status
Indications
- Solid Tumors
Partner

Technology
Product Candidate
JNJ-78278343
Phase: Phase 1
Partner:

JNJ-78278343
(CD3 x KLK2)
Product Status
Indications
- Castration-Resistant Prostate Cancer
Partner

Technology
Product Candidate
Bispecific
Phase: Pre-clinical
Partner:

Product Candidate
Bispecific
Phase: Pre-clinical
Partner:

Bispecific
Product Status
Indications
- Immuno-Oncology
Partner

Technology
Product Candidate
Bispecific
Phase: Pre-clinical
Partner:

Product Candidate
Bispecific
Phase: Pre-clinical
Partner:
